An important aspect of our center's research are medical treatment studies, called clinical trials. These studies provide a controlled and monitored environment where volunteer research participants can safely take experimental medication. Most of the trials at our center are placebo-controlled, double-blind studies, meaning that there is a chance that participants will be on the experimental medication or on a placebo (a substance that looks the same but contains no medication).
On this page, you will find basic information about the clinical trials for which we are currently enrolling at the ADRC. Please find additional UW clinical trial offerings relevant to Alzheimer and frontotemporal degeneration on the UW Memory and Brain Wellness Center's clinical trial list. In general, calling us is the best way to find out if you or a loved one is eligible for a study.
A note about the location of our studies:
The ADRC studies take place at the Harborview Medical Center, and some are located at the Seattle VA Puget Sound location. In addition, for some of our studies, we are able to see participants at the Tacoma (American Lake) VA Puget Sound location. If you have any questions, contact us at 206.897.6609 or email@example.com.
Currently Enrolling Studies
A Multi-Center, Double-Blind, Placebo-Controlled Phase 11a Study to Evaluate an Investigational Medicine to Treat Mild Alzheimer's Disease. The CONNECT Study will test whether an experimental drug, AZD0530 (saracatinib) will slow the progression in mild-stage Alzheimer's disease.
Key UW researcher: Elaine Peskind, MD
Study Coordinator: Anita Ranta, firstname.lastname@example.org or 206.764.2339
The Study of Nasal Insulin to Fight Forgetfulness (SNIFF)
This Phase II/III clinical trial will examine whether a type of insulin, when administered intranasally (as a nasal spray), improves memory in adults with a mild cognitive impairment or Alzheimer’s disease. The study will also provide evidence about how intranasal insulin works in the body.
Key UW researcher: Elaine Peskind, MD
Study Coordinator: Anita Ranta, email@example.com or 206.764.2339
This three-year study will evaluate a new drug that may reduce the impact of Alzheimer’s-related protein plaques in individuals at risk for developing the disease. Scientists believe that the slow accumulation of these neurotoxic amyloid plaques in the brain over many years may cause Alzheimer’s disease (AD) to begin developing long before symptoms appear. Thus, this study will enroll people between the ages of 65 and 85 with normal thinking and memory functioning but with evidence of amyloid plaque buildup in the brain. Half of the participants will receive the study drug while the other half will receive a substance that has no active ingredients in it. Each participant will visit the study site once a month for an intravenous infusion of the study drug or placebo. An extension study may be available at the conclusion that allows everyone to take the study drug.
Key Researcher: Elaine Peskind, MD
Study Coordinator: Anita Ranta | firstname.lastname@example.org
Study Contact Number: 206.764.2069 or 1.800.317.5382
Health Action to Benefit Independence and Thinking (HABIT): A 10-Day Brain and Body Wellness Program for people living with mild cognitive impairment and a support partner
The Comparative Effectiveness of Behavioral Interventions to Prevent or Delay Dementia (CEBIPODD) Study of HABIT
HABIT is a 10-day program offered to individuals with cognitive impairment. A support partner is required to complete the program with the participant. The program builds on existing strengths and recognizes that procedural memory, otherwise known as 'habit,' can be exercised to promote the highest level of function and independence.
In the CEPIPODD study, participants will be randomly assigned to engage daily in 4 of these 5 components of HABIT:
- Individual memory compensation training
- Group supportive therapy
- Brain fitness
- Wellness education
These sessions are delivered by a caring, multidisciplinary HABIT team including psychologists, education specialists, cognitive interventionalists, and exercise specialists.
Key UW Researcher: Vaishali Phatak
Study Contact: Marigrace Becker at email@example.com | 206.744.2017
The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer Disease Caused by a Genetic Mutation.
DIAN-TU is the first prevention trial for Autosomal Dominant Alzheimer’s Disease (ADAD) families. The DIAN-TU trial focuses on drugs that could potentially change the course of the disease. The goal is to determine the safety, tolerability, and effectiveness of these drugs. The DIAN-TU trial will determine if these medications can prevent, delay, or possibly even reverse Alzheimer’s disease changes in the brain.
Although there are differences between ADAD and the more common age-associated, sporadic Alzheimer’s disease, the results of the studies conducted by this unit will have implications for future studies and treatments in sporadic Alzheimer’s disease. Currently the DIAN-TU-001 treatment trial is the only ongoing, active clinical trial within the DIAN-TU. The Enrollment Criteria for this trial can be found on the trial brochure link below. As new trials become available, information will continue to be posted.
Key UW Researcher: Suman Jayadev, MD
Study Contact: The DIAN Expanded Registry at www.DIANexr.org or 1-844-DIAN-EXR (342-6397)
You may be eligible for DIAN-2 if you answer ‘Yes’ to all of the following:
- Does your family have an ADAD mutation (PSEN1, PSEN2, or APP) for early onset Alzheimer’s disease (less than 60 years) in multiple generations?
- Are you cognitively normal, or do you have mild dementia? Both are eligible for this prevention trial.
- Are you between the ages 18 to 80?
- Are you between 15 years younger to 10 years older than your parent was when they first showed the signs of Alzheimer’s disease?
- Do you have a family member or friend that can accompany you to visits and provide information about your medical history?
18F-AV-1451 Autopsy Study
Avid Radiopharmaceuticals is evaluating a new imaging tracer, 18F-AV-1451, to see if it can identify the build-up of tau protein associated with Alzheimer’s disease and other conditions that lead to dementia. Tau accumulation in the brain can gradually cause problems with thinking and remembering. Until now, these tau tangles could only be seen by using a microscope to look at the brain of a patient after they died. This study aims to determine if, using 18F-AV-1451, it may be possible to see tangles in the living brain using a Positron Emission Tomography (PET) scan.
This study is seeking hospice patients, aged 50 and older, who are willing to help achieve this goal of improved Alzheimer’s diagnosis. However, volunteers do not need to have Alzheimer’s or dementia. Participation involves a brief screening visit (which can take place at home), a 18F-AV-1451 PET scan at Harborview Medical Center, and consent to an examination of their brain after they die. The findings in their brain autopsy would then be compared to their PET scan to determine if 18F-AV-1451 truly provides a valid measure of the presence or absence of neurofibrillary tangles.
UW Medicine will provide round-trip transportation for the participant to come in to Harborview for a PET scan. Participants will be reimbursed $100 for the initial screening visit and $250 for the scan. Brain autopsy results will be made available to the participant’s family.
Key UW researcher: Kimiko Domoto-Reilly
Study Coordinator: Margaret Chute at firstname.lastname@example.org or 206-543-9835
Department of Defense Alzheimer's Disease Neuroimaging Initiative (DOD ADNI) Study for Vietnam Era Veterans
Traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) are common combat related problems and may be associated with a greater risk of Alzheimer’s disease. The purpose of this study is to examine the possible connections between TBI and PTSD, and the signs and symptoms of Alzheimer’s disease on Veterans as they age. The information we collect will help us to learn more about how these injuries may affect Veterans of the Vietnam War as they grow older, as well as Veterans of the current wars in Iraq and Afghanistan, who also have these types of combat related injuries.
Neuroimaging and Function Study- UW Rehabilitation Medicine
The purpose of this study is to examine the relationship between brain regions, physical performance and cognitive function in older adults with memory problems. The study involves two visits (one year apart) to the University of Washington Health Sciences Center. At the first visit a magnetic resonance imaging (MRI) is taken of the brain. Walking, balance and memory tests are completed. At the second visit only walking, balance and memory tests are completed. Taxi transportation is provided if needed. Participants receive $50 for the first visit and $30 for the second visit.
Key Researcher: Ellen McGough, PhD
Study Coordinator: Monica Smersh
Study Contact Number: 206-598-6139 or 206-616-5550
Continuing Studies (Not Currently Enrolling)
Even after a study has stopped enrolling subjects, the work still continues. Often, our researchers follow participants in studies for a continued period of time after the study has closed enrollment, monitoring the effects of experimental medications and the changes occurring throughout the study. The studies we are continuing at our center are listed below.
- The SimBio Study (more information here: The SimBio Study Story; Study Flyer; Initial Study Paper)
- Lilly LZAN (click here for more information)
- Janssen AI 251 (click here for more information)
- Resveratrol for Alzheimer's Disease (click here for more information)
- HEART (Health, Education, Aerobic, & Resistance Training) Study for African Americans (click here for the brochure)
- Prazosin for Agitation in Alzheimer's (The Story of Prazosin in Alzheimer's; Study Brochure; Initial Study Paper)
- LZAX Study: Solanezumab for the Treatment of Mild Alzheimer’s
- Early Stage Memory Loss Study Flyer
- Reducing Disabilities in Alzheimer’s Disease Study Flyer
- NOURISH AD Study Study Flyer